SCHEMBL24902183

SCHEMBL24902183

CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4c3ccn4C(=O)C(C)c3ccc(CC(C)C)cc3)cn2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 19/20 0.54
JAK2 O60674 19/20 0.54
JAK3 P52333 14/20 0.54
TYK2 P29597 4/20 0.54
CIT O14578 1/20 0.54
GAK O14976 1/20 0.54
ROCK2 O75116 1/20 0.54
ULK1 O75385 1/20 0.54
PRKCB P05771 1/20 0.54
RET P07949 1/20 0.54
PRKCA P17252 1/20 0.54
PRKACA P17612 1/20 0.54
MARK3 P27448 1/20 0.54
STAT3 P40763 1/20 0.54
CLK1 P49759 1/20 0.54
CSNK1G2 P78368 1/20 0.54
PRKCD Q05655 1/20 0.54
MAP3K1 Q13233 1/20 0.54
ROCK1 Q13464 1/20 0.54
TNK1 Q13470 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24902138 1.00 JAK1 (0.54) JAK1JAK2JAK3TYK2CIT
SCHEMBL24902143 0.90 JAK2 (0.43) JAK1JAK2JAK3TYK2CIT
SCHEMBL27246173 0.88 JAK1 (0.52) JAK1JAK2JAK3TYK2CIT
SCHEMBL24902020 0.88 JAK1 (0.49) JAK1JAK2JAK3TYK2CIT
SCHEMBL30223620 0.88 JAK1 (0.52) JAK1JAK2JAK3TYK2CIT
SCHEMBL24902114 0.88 JAK1 (0.52) JAK1JAK2JAK3TYK2CIT
SCHEMBL24902014 0.88 JAK1 (0.52) JAK1JAK2JAK3TYK2CIT
SCHEMBL24902007 0.87 JAK1 (0.48) JAK1JAK2JAK3TYK2CIT
SCHEMBL24902136 0.86 JAK2 (0.51) JAK1JAK2JAK3TYK2CIT
SCHEMBL26610252 0.86 JAK2 (0.51) JAK1JAK2JAK3TYK2CIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250241921-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) 2025-07-31 US disclosed
US-20250241922-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) 2025-07-31 US disclosed
US-12290519-B2 Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2025-05-06 US disclosed
US-20240197741-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF COVAL BIOPHARMA(SHANGHAI)CO., LTD. (CN) 2024-06-20 US disclosed
CN-117355527-B Anti-inflammatory coupling compound medicine and preparation method and application thereof 上海椿安生物医药科技有限公司 2024-06-07 CN disclosed
EP-4357346-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF Coval Biopharma (Shanghai) Co., Ltd. (CN) 2024-04-24 EP disclosed
CN-117355527-A External anti-inflammatory coupling compound medicine and preparation method and application thereof 上海椿安生物医药科技有限公司 2024-01-05 CN disclosed
WO-2023001045-A9 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海椿安生物医药科技有限公司 2023-10-26 WO disclosed
WO-2023001045-A9 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海椿安生物医药科技有限公司 2023-10-26 WO disclosed
WO-2023001045-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海椿安生物医药科技有限公司 2023-01-26 WO disclosed
WO-2023001045-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海椿安生物医药科技有限公司 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250241921-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF JAK1, TNF, CYP4A11 JAK1 1/4885JAK2 4/4885JAK3 20/4885
US-12290519-B2 Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof JAK1, TNF, CYP4A11 JAK1 1/4885JAK2 4/4885JAK3 20/4885
US-20250241922-A1 ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF JAK1, TNF, CYP4A11 JAK1 1/4885JAK2 4/4885JAK3 20/4885
US-20240197741-A1 EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF TNF, CYP4A11, JAK1 JAK1 3/4885JAK2 4/4885JAK3 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.